Transitioning to Value-Based Healthcare: Challenges and Innovations

"We live in a world where we use millions of variables to predict which ad you're going to click on. Whether or not you deserve to get a loan. What movie you might watch next. But when it comes to our bodies and even serious diseases, we want to reduce things down to just one or two variables." It's insane that we actually collect so little data about our bodies. The modern day physical is downright spartan in what it captures, not to mention that we're using 200-year old tools to capture that very limited data.

Which is why we need to borrow from other domains of science and data and apply that to our bodies, in more ways than one, argues Q founder and CEO Jeffrey Kaditz with a16z bio fund general partner Vijay Pande (in conversation with Sonal Chokshi) on this episode of the a16z Podcast. But how do we get there? What would data "rights" look like -- and could we possibly donate data much like we currently donate organs? And for catching diseases like prostate or breast cancer early, how can we use data captured over multiple points in time -- something not really done right now in medicine -- to be more predictive, sensitive, and specific beyond so-called "representative" population samples? What IS a 'diagnostic', really, anyway?

The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation.

This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/.

Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.